Cost-effectiveness of first-line ribociclib use vs palbociclib in the treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2

Background: The combination of a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus aromatase inhibitor is the standard of care in first-line (1L) treatment of hormone receptor–positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC). Among the 3 CDK4/6is, only ribociclib has shown a statistically significant benefit in overall survival (OS) (MONALEESA [ML]-2 and -7) in 1L use: palbociclib did not demonstrate a significant OS benefit (PALOMA-2 [PAL-2]) and the final OS results for abemaciclib (MONARCH-3) are pending.